Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease by Ulrich, S et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Sequence variants in BMPR2 and genes involved in the
serotonin and nitric oxide pathways in idiopathic pulmonary
arterial hypertension and chronic thromboembolic pulmonary
hypertension: relation to clinical parameters and comparison
with left heart disease
Ulrich, S; Szamalek-Hoegel, J; Hersberger, M; Fischler, M; Solera Garcia, J; Huber, L
C; Grünig, E; Janssen, B; Speich, R
Ulrich, S; Szamalek-Hoegel, J; Hersberger, M; Fischler, M; Solera Garcia, J; Huber, L C; Grünig, E; Janssen, B;
Speich, R (2010). Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in
idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to
clinical parameters and comparison with left heart disease. Respiration, 79(4):279-287.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Ulrich, S; Szamalek-Hoegel, J; Hersberger, M; Fischler, M; Solera Garcia, J; Huber, L C; Grünig, E; Janssen, B;
Speich, R (2010). Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in
idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to
clinical parameters and comparison with left heart disease. Respiration, 79(4):279-287.
Ulrich, S; Szamalek-Hoegel, J; Hersberger, M; Fischler, M; Solera Garcia, J; Huber, L C; Grünig, E; Janssen, B;
Speich, R (2010). Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in
idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to
clinical parameters and comparison with left heart disease. Respiration, 79(4):279-287.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Ulrich, S; Szamalek-Hoegel, J; Hersberger, M; Fischler, M; Solera Garcia, J; Huber, L C; Grünig, E; Janssen, B;
Speich, R (2010). Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in
idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to
clinical parameters and comparison with left heart disease. Respiration, 79(4):279-287.
Sequence variants in BMPR2 and genes involved in the
serotonin and nitric oxide pathways in idiopathic pulmonary
arterial hypertension and chronic thromboembolic pulmonary
hypertension: relation to clinical parameters and comparison
with left heart disease
Abstract
Background: Idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) share important pathogenic and clinical features. BMPR2 mutations
are important in the pathogenesis of IPAH, but little is known about the genetic background in CTEPH.
Objective: To search for mutations and polymorphisms in genes involved in the BMPR2, serotonin and
nitric oxide pathways possibly associated with pulmonary and cardiac disorders in IPAH and CTEPH.
Methods: In a cohort of Swiss patients with IPAH (n = 16) and CTEPH (n = 16), and in 24 controls with
left heart disease without PH, polymorphisms in the BMPR2, 5-HHT, 5-HTR-2A and eNOS genes were
analyzed and correlated with various clinical, functional and hemodynamic parameters. Results: We
found a BMPR2 missense mutation in a patient with coronary artery disease (CAD) without PH but no
BMPR2 mutations in our collective with late-onset sporadic PH. In patients with polymorphic variants
of the BMPR2 gene, the number of blood platelets and oxygen saturation were increased. The c.600A ]
C synonymous variant was associated with worse exercise capacity and decreased quality of life in PH.
We found no significant differences for any measured parameter according to the eNOS, 5-HTR2A and
the 5-HTT polymorphisms, although there was a higher allelic frequency of the 5-HTT long variant in
IPAH than in CTEPH and controls. Conclusion: Our first report of a BMPR2 mutation in a patient with
CAD without PH is interesting and warrants further investigation. Our study may reflect the clinical
status and genetic background in a typical PH cohort as seen in a single tertiary care referral center. 
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hemodynamic parameters.  Results: We found a  BMPR2 mis-
sense mutation in a patient with coronary artery disease 
(CAD) without PH but no  BMPR2 mutations in our collective 
with late-onset sporadic PH. In patients with polymorphic 
variants of the  BMPR2  gene, the number of blood platelets 
and oxygen saturation were increased. The c.600A ] C syn-
onymous variant was associated with worse exercise capac-
ity and decreased quality of life in PH. We found no signifi-
cant differences for any measured parameter according to 
the  eNOS, 5-HTR2A and the  5-HTT polymorphisms, although 
there was a higher allelic frequency of the  5-HTT long variant 
in IPAH than in CTEPH and controls.  Conclusion: Our first re-
port of a  BMPR2 mutation in a patient with CAD without PH 
is interesting and warrants further investigation. Our study 
may reflect the clinical status and genetic background in a 
typical PH cohort as seen in a single tertiary care referral cen-
ter.  Copyright © 2009 S. Karger AG, Basel 
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 Abstract 
 Background: Idiopathic pulmonary arterial hypertension 
(IPAH) and chronic thromboembolic pulmonary hyperten-
sion (CTEPH) share important pathogenic and clinical fea-
tures.  BMPR2  mutations are important in the pathogenesis 
of IPAH, but little is known about the genetic background in 
CTEPH.  Objective: To search for mutations and polymor-
phisms in genes involved in the BMPR2, serotonin and nitric 
oxide pathways possibly associated with pulmonary and 
cardiac disorders in IPAH and CTEPH.  Methods: In a cohort 
of Swiss patients with IPAH (n = 16) and CTEPH (n = 16), and 
in 24 controls with left heart disease without PH, polymor-
phisms in the  BMPR2, 5-HHT, 5-HTR-2A and  eNOS genes were 
analyzed and correlated with various clinical, functional and 
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 Introduction 
 Idiopathic pulmonary arterial hypertension (IPAH) 
and chronic thromboembolic pulmonary hypertension 
(CTEPH) belong to the group of pulmonary vascular dis-
orders classified by the World Health Organization and 
defined by mean pulmonary artery pressure  6 25 mm Hg 
at rest  [1] . Structural and functional changes in the vas-
cular wall and thrombus formation are the main factors 
responsible for increased pulmonary vascular resistance 
in patients with pulmonary hypertension (PH)  [2, 3] . The 
contribution of each of these factors is thought to be dif-
ferent among the variable underlying causes of PH  [4] . 
Despite these presumptive distinctions, differently clas-
sified PH such as IPAH and CTEPH share important 
pathogenetic and clinical features. Favorable effects of 
vasodilator and antiproliferative agents are not only seen 
in IPAH but also in CTEPH  [5–9] : both disorders share 
acute vasodilator properties  [10] and a comparable pul-
monary vessel histology at advanced disease  [11] .
 Since the description of heterozygous mutations in the 
bone morphogenetic protein type II receptor ( BMPR2 
gene) in patients with PH  [12, 13] , it has become widely 
accepted that alternations in the transforming growth 
factor (TGF)-  pathway, to which  BMPR2 belongs, play 
an important role in PH development  [14–16] . Although 
 BMPR2  mutations are the underlying cause in  1 70% of 
familial and 11–26% of sporadic IPAH cases  [12–14, 17, 
18] , only a minority of patients with  BMPR2 mutations 
develop clinical PH due to markedly reduced penetrance 
 [14, 19, 20] .
 Hence, there must be other factors which, in addition 
to or in combination with the  BMPR2 mutations, play a 
pathogenetic role in the development of PH. These sec-
ond or third pathogenetic ‘hits’ might be other genetic or 
environmental factors, or both interplaying with each 
other. In this study, we aimed to investigate some genetic 
factors possibly contributing to the pathogenesis of the 
two major forms of PH (IPAH and CTEPH).
 Beside some rare cases of BMPR2  mutations found in 
patients with congenital heart disease-associated PH  [21] 
and pulmonary veno-occlusive disease  [22, 23] , little is 
known about  BMPR2 mutations in other forms of PH, e.g. 
CTEPH. A recent British study characterizing CTEPH 
patients did not find  BMPR2  mutations in  1 100 subjects 
 [24] .
 Among other genetic factors, which were suggested to 
affect the pathogenesis of PH, there are polymorphisms 
in the serotonin transporter  (5-HTT) or receptor  (5-HTR) 
genes or, in analogy to left heart diseases, polymorphisms 
in the nitric oxide (NO) system  [2, 25, 26] . The long al-
lelic variant in  5-HTT has been found to be associated 
with PH severity in  patients with chronic obstructive 
pulmonary disease  [27] but not in IPAH  [28] . 5-HTR has 
been reported to play an important role in vasoconstric-
tion and proliferation of vessel walls  [29] . The c.102T ] C 
polymorphism of the  5-HTR2A gene has been associated 
systemic arterial hypertension  [30–32] but has not been 
investigated in PH. Therefore, we decided to include this 
gene in our analysis. NO plays a key role in endothelial 
dysfunction  [33] , and the expression of the endothelial 
NO synthase  (eNOS) is modified in PH  [34] . Polymor-
phisms in the  eNOS gene have been related to coronary 
artery disease (CAD)  [35] and to high-altitude pulmo-
nary edema in Japanese and Indian populations  [36, 37] 
but not in Caucasians  [38] . At this background, we have 
chosen to investigate the  4a/b and the p. Glu298Asp poly-
morphisms of eNOS in our patient cohort.
 The aim of the present study was to prospectively in-
vestigate genetic variants in  BMPR2  and some potential-
ly interesting variants in  5-HTT ,  5-HTR2A  and  eNOS in 
consecutive patients with IPAH and CTEPH and to look 
for associations with clinical, functional and hemody-
namic parameters. As controls, exercise-limited patients 
with left heart disease not suffering from PH were in-
cluded.
 Patients and Methods 
 Study Population 
 Between October 2004 and May 2006, consecutive patients 
with IPAH and CTEPH seen at the PH clinic of the University 
Hospital of Zurich, Switzerland, were prospectively included 
upon written informed consent. PH was defined as mean pulmo-
nary arterial pressure  6 25 mm Hg with a pulmonary capillary 
occlusion pressure  ^  15 mm Hg by right heart catheterization. 
IPAH was diagnosed if a thorough evaluation by medical history, 
echocardiography, rheumatologic examination, antibody screen-
ing and additional tests if required according to best clinical prac-
tice (e.g. pulmonary function tests, blood gas assessment, tho-
racic computed tomography, coronary angiography and rheuma-
tologic evaluation) did not reveal any other cause for elevated 
pulmonary pressure  [1] . In every patient, a detailed family history 
has been obtained, and a pedigree has been constructed. CTEPH 
was diagnosed by both radioisotope ventilation-perfusion scan 
and pulmonary angiography  [39] .
 In the control patients, PH was excluded either by heart cath-
eterization or echocardiography, and assessment of genetics, and 
clinical and functional parameters was similar to the PH group. 
The study was approved by the local ethics committee.
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 General Study Assessments 
 Patient’s demographics (age, sex, height, weight and calculated 
body mass index in kg/m 2 ), history, drug use, New York Heart 
Association (NYHA) functional class, 6-min walk distance 
(6MWD) and Borg dyspnea scale score were assessed. Quality of 
life (QoL) was measured by the Minnesota Living with Heart Fail-
ure Questionnaire, with higher scores representing worse QoL 
 [40] . NT-pro brain natriuretic peptide, C-reactive protein (using 
a highly sensitive method, CRPsens), uric acid, creatinine, albu-
min, bilirubin, calcium, and erythrocyte, leukocyte and throm-
bocyte counts were assessed. 
 Genetic Analysis 
 EDTA-supplemented blood samples were collected and DNA 
was extracted with the QIAamp  DNA Mini Kit (Qiagen, Basel, 
Switzerland). Primers were designed with the Oligo 4.0 software 
(MedProbe, Oslo, Norway) and with the Primer3 Program (http://
primer3.sourceforge.net/), and purchased from Microsynth (Bal-
gach, Switzerland) or from Eurofins MWG Operon (Ebersberg, 
Germany).
 BMPR2 Mutation and Polymorphism Analysis 
 BMPR2 mutation analysis was performed in the Institute of 
Human Genetics in Heidelberg in all index patients and controls 
using denaturating high-performance liquid chromatography 
and cycle sequencing with the BigDye terminator kit (V1.1, Ap-
plied Biosystems, Darmstadt, Germany) on an ABI 3700 sequenc-
er as described previously ( table 1 )  [17] . Genetic investigators were 
blinded to the clinical data. To determine the significance of the 
c.818T ] G (p.Met273Arg) mutation for pre-mRNA splicing, the 
 BMPR2 transcript was analyzed by RT-PCR as previously de-
scribed  [17] .
 5-HTT Polymorphisms 
 The 44-bp insertion/deletion polymorphism in  5-HTT was 
analyzed using 5-HTT primers and the Expand Long Template 
Kit from Roche Molecular Biochemicals (Rotkreuz, Switzerland). 
PCR resulted in a long (L) amplification product of 457 bp and in 
a short (S) amplification product of 414 bp for the two alleles, 
which were separated on agarose gels.
 c.102T ] C Polymorphism of HTR2A 
 For the detection of the c.102T ] C polymorphism in the 
 HTR2A gene, a LightCycler assay was developed and four oligo-
nucleotides were added to the LightCycler DNA Master Hybrid-
ization Probes mixture (Roche Molecular Biochemicals); a melt-
ing curve analysis was performed from 40 to 85 ° C at a linear rate 
of 0.1 ° C/s  [41] .
 4a/b Polymorphism of eNOS 
 eNOS4a is a rare short allele with 4 tandem 27-bp repeats and 
eNOS4b is a large allele with 5 tandem repeats. Genotyping of the 
27-bp repeat in intron 4 of the  eNOS gene (eNOS4a/b) was per-
formed according to Wang et al.  [42] .
 Glu298Asp Polymorphism of eNOS 
 For the detection of the p.Glu298Asp polymorphism in  eNOS , 
a 25-  l tetraprimer PCR was developed using the Amplitaq
Gold TM System (Perkin-Elmer, Hünenberg, Switzerland) and ap-
plied as previously described  [43, 44] .
Table 1. PCR and sequencing primers used for the BMPR2 mutation analysis
BMPR2 exon Forward primer (5]3) Reverse primer (5]3) Annealing
temperature, ° C
1 gtgatacgggcaggatcagt atttccctggaaggcatgg 61
2 gtcattcggataagacaaa tttaacatactcccatgtcc 54
3 tagcttacacgtactctcac cctggcttcaaccttgaatg 58
4 gggtacagcctttctaaagg gatactattgaggctgggtg 61
4 (sequencing primer) tgacatttcaaaatttgttttcttt
5 gctgctaatctttctgcagc gaatgaagtcactgttccag 61
6 cagagagctgtagcattctg aagtgatccacctgccttag 58
7 tttgcaaattctttataaggatgc ttcctgttgtgaattttgaacc 56
7 (sequencing primer) cgcattttttcctctata
8 gttattagaaaattaatgggcaga ttatcatttcaaagtacatcagtg 56
9 agaatatgctacgttctctc acactagatagcaatgaactaaagg 56
10 ttggtatcagaaatacccctgtt caaacaacattaaaacatattcagtca 56
11 cacatggtttgacatgtactttg tcattgaactattaggctggttt 54
12 (fragment 12-1) aaatttggagagacagtttgtca ttcatctgggtatggcatctc 58
12 (fragment 12-2) agcaagcacaagctcgaatc agtcctgctgtccagttgct 58
12 (fragment 12-3) tctagcttgctttacccact agcatgggagttaacactgt 58
12 (fragment 12-4) acctcatgtggtgacagtca attggaattagttcggccac 56
12 (fragment 12-5) attccagtcctgatgagcat agttatttaaatggccccaa 56
13 caccctcctgagacattggt catcttctgcatgtttaaatga 55
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 Statistical Analysis 
 Results are expressed as medians (interquartile ranges) or 
means  8 SD. The Mann-Whitney U test and analysis of variance 
were used to compare means between groups. Fisher’s exact test 
was applied to compare frequencies between groups. Differences 
of p  ! 0.05 were considered statistically significant.
 Results 
 Patient Characteristics 
 PH Study Group. Of the 38 PH patients screened, 6 pa-
tients were excluded for reasons other than PH (2 patients 
with scleroderma and 4 with left heart dysfunction). We 
finally included 16 patients (10 females) with IPAH (age 
65  8 16 years) and 16 patients (9 females) with CTEPH 
(age 65  8 11 years) in the study ( table 2 ). All patients are 
Caucasians. Twenty-four patients were included at the 
time of their first confirmatory right heart catheteriza-
tion and 8 patients at the time of a follow-up catheteriza-
tion. On average, symptoms had started 15  8 11 months 
before diagnosis. All patients were followed up in our PH 
clinic (mean follow-up time 37  8 20 months until data 
analysis). Six patients died (33  8 32 months after diag-
nosis), and 3 patients had successful pulmonary endar-
terectomy. All IPAH patients had a negative family his-
tory of the disease. Nine of the CTEPH patients were clas-
sified as operable by a specialized surgeon (E. Mayer, 
Mainz); however, 6 were not operated on due to patients’ 
wishes or comorbidity. Most patients were in NYHA class 
III or IV. IPAH patients had a significantly lower 6MWD 
compared with CTEPH patients but comparable QoL, 
pro-BNP, uric acid and pulmonary hemodynamics ( ta-
ble 2 ).
 Control Group and Comparison with All PH Patients . 
Twenty-four patients (9 females; age 67  8 12 years) with-
out PH (7 with valvular, 8 with ischemic and 9 patients 
with hypertensive heart disease) were included as con-
trols. PH was excluded by heart catheterization or echo-
cardiography.
 Genetic Analysis 
 BMPR2 Sequence Variants 
 In the present collective, no  BMPR2 mutations were 
found in the 16 study patients with sporadic IPAH and in 
the 16 patients with CTEPH. Interestingly, a c.818T ] G 
(p.Met273Arg) mutation was noted in a patient with CAD 
and impaired left ventricular pump function without PH 
(initial right ventricular pressure 26 mm Hg above the 
Table 2. Characteristics of the patients and controls 
Characteristics IPAH (n = 16) CTEPH (n = 16) Controls (n = 24)
General 
Sex, females/males 10/6 9/7 9/15
Age, years
At study assessment 65816 65811 67812
At first PH-related symptoms 62816 62812
NYHA functional class, II/III/IV 1/8/7 1/10/4 1/10/13
6MWD, m 348885 435864* 288893**
QoL, points
Total 44815 36819 42821
Physical subscore 2487 2086 24810
Emotional subscore 986 1087 687
Pro-BNP (<88 ng/l) 2,30381,810 2,09981,576 3,61783,501
Uric acid (150–300 mol/l) 4628144 4708140 4888178
Pulmonary hemodynamics 
Mean pulmonary arterial pressure, mm Hg 48810 41810
Pulmonary vascular resistance, dyn  s  cm5 7488361 7088293
Cardiac index, l/min/m2 2.380.7 2.080.5
Right atrial pressure, mm Hg 1287 1188
Mixed venous oxygen saturation, % 5889 5588
Means 8 SD. * p < 0.05 vs. IPAH, ** p < 0.001, vs. IPAH and CTEPH. Normal range/values are shown in 
parentheses.
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right atrial pressure by echocardiography). This patient 
underwent coronary angioplasty and stenting of his left 
anterior descending artery due to a non-ST elevation 
myocardial infarction. Two years later, he received aorto-
coronary bypass surgery, and after recovery he was clas-
sified in NYHA functional class I. His echocardiograph-
ically measured right ventricular pressure was 19 mm Hg 
3 months after the operation. At the last follow-up, he felt 
well (48 months after inclusion) without any relevant dys-
pnea (NYHA I). His family history was negative for PH, 
dyspnea, sudden deaths or syncopes. The c.818T ] G 
(p.Met273Arg) mutation was proven in two independent 
blood samples. According to the in silico analysis per-
formed with the use of the web resource ESEfinder, this 
missense mutation was predicted to alternate the se-
quence of exonic splicing enhancers. For verification, we 
have conducted RT-PCR analysis on the mRNA of the 
patient and found that the mutation was also present in 
the  BMPR2 transcript and did not influence the proper 
splicing. Nevertheless, the possibility remains that this 
methionine ] arginine exchange affects the function of 
the BMPR2 receptor. This exchange occurred within the 
kinase domain of the BMPR2 receptor in an evolutionary 
highly conserved region of the gene.
 Several intronic and coding polymorphisms of the 
 BMPR2 gene have been reported so far  [23] . In our col-
lective, we detected  BMPR2 polymorphisms in introns
3 and 4, and exons 5 and 12 ( table 3 ). The c.600A ] C
(p.L200L) polymorphism in exon 5 was thereby almost 
exclusively found in IPAH (3 patients), while the c.2324G
 ] A (p.S775N) polymorphism from exon 12 was detected 
in CTEPH patients. The other  BMPR2 polymorphisms 
were found with almost equal distribution between the 
groups. Overall, PH patients with any  BMPR2 polymor-
phisms had lower blood platelet counts and higher oxy-
gen saturations than patients with the wild-type sequence 
(269 vs. 210  10 3 /  l, p = 0.025, and 87.5 vs. 91%, p = 0.028). 
IPAH patients with disease onset below the age of 60 
years (n = 4) were more likely to carry any sequence vari-
ants than patients with a later disease onset ( 1 60 years, 
n = 12): 4/4 versus 4/12. Polymorphisms in CTEPH pa-
tients were more equally distributed for patients with an 
earlier (n = 6) versus late disease onset (n = 10): 2/6 versus 
6/10. PH patients carrying the c.600A ] C (p.L200L) se-
quence variant had a significantly lower 6MWD and 
worse physical subscores in QoL assessments (mean 
6MWD 259 vs. 408 m, p = 0.011, and mean physical QoL 
score 30 vs. 21 points, p = 0.022;  fig. 1 ). Two patients were 
acute responders to inhaled NO during heart catheteriza-
tion, and both did not have  BMPR2 polymorphisms. Four 
of the 6 patients (67%) who died and 10 of the 26 patients 
(38%) who survived until the end of the study had any 
 BMPR2 polymorphism. Event-free survival did not differ 
between carriers of any  BMPR2 polymorphism and non-
carriers until the end of the study.
 Polymorphism of  5-HTT 
 The long allelic variant of the  5-HTT  gene was found 
homozygous in 33, 6 and 20% and heterozygous in 47, 69 
and 54% of patients with IPAH, CTEPH and controls, 
Table 3. BMPR2 sequence variants found in the Swiss collective 
and their frequency distribution within groups
Location Nucleotide 
change
Amino
acid change
Frequencies, %
IPAH CTEPH controls 
Intron 3
and 4
c.420-38delT;
c.529+64C]T
15 20 17
Exon 5 c.600A]C p.L200L 20 0 4
Exon 6 c.818T]G p.M273R 0 0 4
Exon 12 c.2324G]A p.S775N 0 13 4
Exon 12 c.2811G]A p.R937R 20 20 38
200
M
W
D
(m
)
300
400
500
Polymorphism absent Polymorphism present
Exon 5: c.600A C p.L200Lr
7
p = 0.011
 Fig. 1. 6MWD according to the p.L200L BMPR2 polymorphism 
in patients with PH. 
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respectively (nonsignificant;  table 4 ). The allelic frequen-
cy of the L variant was slightly higher in IPAH than in 
CTEPH and in control groups (nonsignificant). There 
were no significant differences in patient characteristics 
according to the  5-HTT polymorphism overall and with-
in each group. Of the patients who succumbed, the long 
allelic variant was found homozygous in 1 and heterozy-
gous in 2 patients.
 c.102T ] C Polymorphism of  5-HTR2A 
 The frequencies of the TT, TC and CC variants in 
IPAH, CTEPH and controls are shown in  table 4 . The al-
lelic frequency for the C and T alleles was similar in all 
groups. No significant differences regarding  5-HTR2A 
variants were found for any parameter measured.
 eNOSb/a 
 The eNOS4a allele was found heterozygous in 33, 31 
and 29% of IPAH, CTEPH and controls and homozygous 
in 0, 6 and 4%, respectively ( table 4 ). The allelic frequen-
cies of the eNOS4a variant were 17, 22 and 19% in IPAH, 
CTEPH and controls, respectively. PH patients with the 
eNOS4a variant tended to have higher pulmonary vascu-
lar resistances (618, 769 and 1,105 dyn  s  m –5  for bb, ab 
and aa, respectively) and lower 6MWD (432, 409 and
413 m for bb, ab and aa, respectively), but the differences 
did not reach statistical significance in this relatively 
small cohort.
 Endothelial NO p.Glu298Asp Polymorphism 
 As shown in  table 4 , the genotype frequencies for
p.Glu298Glu, p.Glu298Asp and p.Asp298Asp were 27,
53 and 20% for IPAH, 56, 44 and 0% for CTEPH and 33, 
50 and 17% for controls, respectively. We could not dem-
onstrate any association of this polymorphism with clin-
ical data and disease severity.
 Discussion 
 In this cross-sectional analysis in a Swiss PH referral 
center, we studied the genetic variants of the  BMPR2 
gene,  serotonin and oxide system and their relationship 
to the various clinical parameters in patients with IPAH 
and CTEPH in comparison to a control group of simi-
larly exercise-limited patients without PH.
 BMPR2 mutations in patients with IPAH are either 
thought to occur in the setting of low-penetrance germ-
line mutations or may arise de novo  [23] . In our cohort, 
we found only one  BMPR2 mutation (p.Met273Arg), sur-
prisingly not in a patient suffering from PH but from 
CAD. This finding is novel and remarkable, and may 
point towards a role of the  BMPR2 pathway in other dis-
eases than PH. A thorough history and clinical examina-
tion did not reveal any sign for PH in this patient or his 
family. The same mutation was previously described in 1 
IPAH case with hypothyroidism  [23] . So far, functional 
studies providing more insight into the consequence of 
this missense mutation are missing. Some missense mu-
tations, especially when located in the proximity of exon/
intron boundaries, may cause aberrant pre-mRNA splic-
ing due to alternations in sequences recognized by vari-
ous splicing factors  [45] . Using RT-PCR analysis, we have 
shown this not to be the case for the p.Met273Arg genet-
ic variant. Further analyses have to be performed in order 
to elucidate the effect of this amino acid exchange on 
proper receptor function as well as in order to exclude a 
possible mosaic state of this alternation. However, due to 
the generally low penetrance of  BMPR2 mutations and 
particularly given the different pathophysiology of PH 
Table 4. Frequencies of the tested 5HTT, 5HTR2a and NO poly-
morphisms in IPAH (n = 16), CTEPH (n = 16) and control groups 
(n = 24)
Subjects Type of poly-
morphism
Genotypes
%
Allele fre-
quencies, %
5HTT SS SL LL S L
IPAH 20 47 33 43 57
CTEPH 25 69 6 59 41
Controls 25 54 20 52 48
5HTR2a TT TC CC T C
IPAH 13 67 20 47 53
CTEPH 6 56 38 34 66
Controls 25 42 33 46 54
eNOS4a/b bb ab aa b a
IPAH 67 33 0 83 17
CTEPH 63 31 6 78 22
Controls 67 29 4 81 19
eNOS298 Glu/
Glu
Glu/
Asp
Asp/
Asp
Glu Asp
IPAH 27 53 20 53 47
CTEPH 56 44 0 78 22
Controls 33 50 17 58 42
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and CAD, it is difficult to estimate whether this mutation 
could somehow have contributed to the patient’s condi-
tion or left ventricular function. Other risk factors, main-
ly his smoking history with 60 pack-years until his first 
event, have to be considered.
 The lack of any detected  BMPR2 mutations in the 
present IPAH cohort is unexpected but possible consider-
ing that the prevalence of  BMPR2 mutations in patients 
with sporadic PAH is only 11–26%  [20, 23, 46] and may 
be even lower, as recently described by Rosenzweig et al. 
 [47] (6.1%). It must, however, be taken into account that 
the screening method applied has several limitations. It 
has a very high detection rate for mutations in the coding 
regions and exon/intron boundaries, but does not allow 
for identification of large exonic deletions or duplica-
tions. The latter are however rare in patients with spo-
radic PAH, in agreement with a previous study (6 of 126 
IPAH patients)  [48] and based on our own observations 
(data not published). Furthermore, putative mutations in 
the untranslated regulatory and intronic sequences of the 
 BMPR2 gene remain undetected  [49] .
 Another possible explanation might be the compara-
tively advanced age of the IPAH patients included in our 
cohort, with average age of disease onset being 61  8 16 
years. Based on other observations,  BMPR2 mutation 
carriers are suspected to develop the symptoms earlier 
than non-carriers  [50] .
 Beside the rare and pathologic mutations, several poly-
morphic variants have also been identified in the se-
quence of the  BMPR2 gene  [23, 51, 52] . The frequencies of 
some of these polymorphisms were studied in several co-
horts of PAH patients and unaffected individuals  [23] . 
The c.600A ] C (p.L200L) polymorphism in exon 5 was 
found in 4% of our controls but in 20% of IPAH patients, 
and it was associated with a significantly lower 6MWD 
and QoL in physical domains ( fig. 1 ). Herewith, we de-
scribe for the first time a higher prevalence of a coding 
 BMPR2 polymorphism in an IPAH cohort with an asso-
ciation to disease severity (assessed by the 6 MWD and 
QoL). As this single-nucleotide polymorphism does not 
lead to the amino acid exchange and is not predicted to 
alternate mRNA splicing, it may not have direct causal 
effects, but may be linked in some patients to another not 
yet identified functional alternation in the  BMPR2 gene. 
This novel finding may suggest that some common ge-
netic variants of the  BMPR2 gene could play a role in the 
modulation of disease severity. In our small cohort, car-
riers of any  BMPR2  polymorphism were more likely to 
have a worse outcome after PH diagnosis (67% of the pa-
tients who died in our cohort were carriers of any poly-
morphism compared with 38% of the survivors); how-
ever, these results have to be verified by investigations in 
larger PH cohorts.
 The L-allelic variant of  5-HTT has been found to be 
associated with disease severity in PH related to chronic 
obstructive lung disease  [27, 53] ; however, this association 
could not be found in IPAH or familial PAH  [28] . In our 
collective, the L-allelic variant was slightly more preva-
lent in IPAH compared with CTEPH or controls; how-
ever, there was no association with clinical parameters or 
event-free survival. The base in nucleotide position 102 
of the  5-HTR2A gene may be thymine (T) or cytosine (C), 
with three possible genotypes, TT, TC or CC. This se-
quence variant does not result in any amino-acid change, 
as both alleles code for a serine in codon 34, but it is sup-
posed to be in linkage disequilibrium with functional  5-
HTR2A gene variants. However, we found no difference 
in the prevalence and clinical presentation according to 
 5-HTR2A variants in PH or controls. Our findings dis-
courage a relevant pathogenetic role of the presently in-
vestigated  5-HTT and  5-HTR2A polymorphisms in IPAH 
or CTEPH.
 The allelic frequency of the eNOS4a variant in the 
present cohort was comparable to Japanese patients with 
high-altitude pulmonary edema and higher than expect-
ed from previously described healthy controls ( table 4 ) 
 [36] , demonstrating a genetic heterogeneity in various 
populations of different ethnicity. A tendency towards 
higher pulmonary vascular resistance and lower exercise 
capacity assessed by 6MWD in  eNOS4a carriers may 
point towards a possibly modulating role of this eNOS 
variant in PH. Concerning the p. Glu298Asp  polymor-
phism, the Asp allelic frequency in CTEPH patients in 
our cohort was similar to that found in Japanese patients 
with high-altitude pulmonary edema  [36] . However, the 
frequencies of the Asp allele in IPAH and controls were 
even higher and similar to a French population  [54] . Con-
sidering the lack of any association of the p.Glu298Asp 
polymorphism with clinical parameters, we suggest that 
this polymorphism might not be significantly involved in 
the pathogenesis of PH.
 Our single center, cross-sectional study bears several 
intrinsic limitations. First, the investigated cohort is 
small; however, PH is a rare disease and significant find-
ings in a small cohort may help to direct future research 
in the field. Our control group consisted of exercise-lim-
ited patients with some form of left heart involvement 
without PH and not healthy controls. However, as  BMPR2 
mutations are thought to be disease specific for PAH, we 
did not expect to find any pathologic  BMPR2 alteration 
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in a patient with CAD. The genetic analyses of our pa-
tients were restricted to the screening for genetic variants 
in  BMPR2 and in three genes of the serotonin and NO 
systems. However, it might be possible that other herein 
not investigated polymorphisms are causally involved in 
the pathogenesis of PH.
 Overall, the present study may reflect the clinical sta-
tus and genetic background in a typical PH cohort as seen 
in a single, tertiary care, referral center. We suggest that 
the results obtained in this study require verification in a 
larger case-control study before any definitive conclu-
sions can be made with respect to the current practical 
relevance.
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